Aprea Therapeutics, Inc. Logo

Aprea Therapeutics, Inc.

Developing precision cancer therapies targeting DNA Damage Response for solid tumors.

APRE | US

Overview

Corporate Details

ISIN(s):
US03836J1025
LEI:
Country:
United States of America
Address:
3805 OLD EASTON ROAD, 18902 DOYLESTOWN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel cancer therapeutics through precision oncology. The company specializes in synthetic lethality-based therapies that target DNA Damage Response (DDR) pathways. Aprea's pipeline features small molecule drug candidates designed to maximize clinical efficacy while minimizing toxicity. The company is actively conducting clinical trials to evaluate its programs in patients with advanced solid tumors, aiming to provide new treatment options and improve outcomes for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aprea Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aprea Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aprea Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD
Tyra Biosciences, Inc. Logo
Biotech developing precision FGFR medicines for cancer and genetic disorders.
United States of America
TYRA
UCB Logo
UCB
Biopharma firm developing treatments for severe neurological and immunological diseases.
Belgium
UCB
Ultragenyx Pharmaceutical Inc. Logo
Develops and commercializes novel therapies for rare and ultra-rare genetic diseases.
United States of America
RARE
Develops biopharma therapies for endocrinology, ophthalmology, and dermatology needs.
Hong Kong
690
Unicycive Therapeutics, Inc. Logo
A clinical-stage biotech developing novel treatments for kidney diseases, led by oxylanthanum carbonate.
United States of America
UNCY
UNION KOREA PHARM CO.,Ltd Logo
Develops and manufactures prescription drugs like antibiotics and analgesics for global markets.
South Korea
080720
uniQure N.V. Logo
Developing AAV-based gene therapies for rare liver and central nervous system disorders.
United States of America
QURE
UNITED THERAPEUTICS Corp Logo
Develops therapies for chronic diseases and manufactures organs for transplantation.
United States of America
UTHR
Universe Pharmaceuticals INC Logo
Manufactures, markets, and distributes TCM derivative products and biomedical drugs.
United States of America
UPC

Talk to a Data Expert

Have a question? We'll get back to you promptly.